187 related articles for article (PubMed ID: 20573638)
21. Sample size calculation based on efficient unconditional tests for clinical trials with historical controls.
Shan G; Moonie S; Shen J
J Biopharm Stat; 2016; 26(2):240-9. PubMed ID: 25551261
[TBL] [Abstract][Full Text] [Related]
22. Sample size estimation for GEE method for comparing slopes in repeated measurements data.
Jung SH; Ahn C
Stat Med; 2003 Apr; 22(8):1305-15. PubMed ID: 12687656
[TBL] [Abstract][Full Text] [Related]
23. Using horseshoe prior for incorporating multiple historical control data in randomized controlled trials.
Ohigashi T; Maruo K; Sozu T; Gosho M
Stat Methods Med Res; 2022 Jul; 31(7):1392-1404. PubMed ID: 35379046
[TBL] [Abstract][Full Text] [Related]
24. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
Lui KJ; Chang KC
Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
[TBL] [Abstract][Full Text] [Related]
25. Minimum number of clusters and comparison of analysis methods for cross sectional stepped wedge cluster randomised trials with binary outcomes: A simulation study.
Barker D; D'Este C; Campbell MJ; McElduff P
Trials; 2017 Mar; 18(1):119. PubMed ID: 28279222
[TBL] [Abstract][Full Text] [Related]
26. Sample Size Estimation in Clinical Research: From Randomized Controlled Trials to Observational Studies.
Wang X; Ji X
Chest; 2020 Jul; 158(1S):S12-S20. PubMed ID: 32658647
[TBL] [Abstract][Full Text] [Related]
27. Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.
Graf AC; Bauer P
Stat Med; 2011 Jun; 30(14):1637-47. PubMed ID: 21495058
[TBL] [Abstract][Full Text] [Related]
28. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
29. Incorporating historical two-arm data in clinical trials with binary outcome: A practical approach.
Feißt M; Krisam J; Kieser M
Pharm Stat; 2020 Sep; 19(5):662-678. PubMed ID: 32227680
[TBL] [Abstract][Full Text] [Related]
30. Sample size recalculation in multicenter randomized controlled clinical trials based on noncomparative data.
Harden M; Friede T
Biom J; 2020 Sep; 62(5):1284-1299. PubMed ID: 32128868
[TBL] [Abstract][Full Text] [Related]
31. Randomized Controlled Trials 6: Determining the Sample Size and Power for Clinical Trials and Cohort Studies.
Greene T
Methods Mol Biol; 2021; 2249():281-305. PubMed ID: 33871850
[TBL] [Abstract][Full Text] [Related]
32. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study.
Teare MD; Dimairo M; Shephard N; Hayman A; Whitehead A; Walters SJ
Trials; 2014 Jul; 15():264. PubMed ID: 24993581
[TBL] [Abstract][Full Text] [Related]
33. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
Sawamoto R; Oba K; Matsuyama Y
Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
[TBL] [Abstract][Full Text] [Related]
34. Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.
Neven A; Mauer M; Hasan B; Sylvester R; Collette L
J Biopharm Stat; 2020 Mar; 30(2):305-321. PubMed ID: 31331234
[TBL] [Abstract][Full Text] [Related]
35. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
Rasmussen HE; Ma R; Wang JJ
Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
[TBL] [Abstract][Full Text] [Related]
36. A Comparison Between a Meta-analytic Approach and Power Prior Approach to Using Historical Control Information in Clinical Trials With Binary Endpoints.
Isogawa N; Takeda K; Maruo K; Daimon T
Ther Innov Regul Sci; 2020 May; 54(3):559-570. PubMed ID: 33301135
[TBL] [Abstract][Full Text] [Related]
37. The optimal design of stepped wedge trials with equal allocation to sequences and a comparison to other trial designs.
Thompson JA; Fielding K; Hargreaves J; Copas A
Clin Trials; 2017 Dec; 14(6):639-647. PubMed ID: 28797179
[TBL] [Abstract][Full Text] [Related]
38. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
39. Sample size considerations for GEE analyses of three-level cluster randomized trials.
Teerenstra S; Lu B; Preisser JS; van Achterberg T; Borm GF
Biometrics; 2010 Dec; 66(4):1230-7. PubMed ID: 20070297
[TBL] [Abstract][Full Text] [Related]
40. Designing historical control studies with survival endpoints using exact statistical inference.
Han G
Pharm Stat; 2021 Jan; 20(1):4-14. PubMed ID: 32743949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
